Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 18/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30116411 | 1.00 | RORC (0.54) | RORCCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL23488034 | 0.94 | RORC (0.48) | RORCCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL30116394 | 0.92 | RORC (0.47) | RORCCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL30116405 | 0.92 | RORC (0.45) | RORCCYP2C9CYP2C19 | |
| SCHEMBL23000373 | 0.92 | RORC (0.45) | RORCCYP2C9CYP2C19 | |
| SCHEMBL23000475 | 0.92 | RORC (0.47) | RORCCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL30116492 | 0.90 | RORC (0.44) | RORCCYP2C9CYP2C19 | |
| SCHEMBL23000395 | 0.90 | RORC (0.44) | RORCCYP2C9CYP2C19 | |
| SCHEMBL23000322 | 0.90 | RORC (0.47) | RORCCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL30116501 | 0.90 | RORC (0.47) | RORCCYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-01-07 | — | — | US | disclosed |
| CN-116514722-A | Benzimidazole derivatives as modulators of retinoic acid related orphan receptor gamma (ROR gamma) and pharmaceutical uses thereof | 江苏恒瑞医药股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3781161-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORY) AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2023-06-07 | — | — | EP | disclosed |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| CN-112135611-B | Benzimidazole derivatives as modulators of retinoic acid-related orphan receptor gamma (ROR γ) and pharmaceutical uses thereof | 江苏恒瑞医药股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11512055-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-11-29 | — | — | US | disclosed |
| US-20210171471-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Uses Thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-06-10 | — | — | US | disclosed |
| US-20210171471-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Uses Thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-06-10 | — | — | US | disclosed |
| EP-3781161-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORY) AND PHARMACEUTICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| CN-112135611-A | Benzimidazole derivatives as modulators of retinoic acid-related orphan receptor gamma (ROR γ) and pharmaceutical uses thereof | 江苏恒瑞医药股份有限公司 | 2020-12-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171471-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Uses Thereof | RORB, RORA, RORC | RORC 3/4885CYP2C9 373/4885CYP2C19 380/4885 |
| US-11512055-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof | RORC, RORB, RORA | RORC 1/4885CYP2C9 329/4885CYP2C19 287/4885 |
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | RORC, RORB, RORA | RORC 1/4885CYP2C9 303/4885CYP2C19 262/4885 |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | RORB, RORA, RORC | RORC 3/4885CYP2C9 342/4885CYP2C19 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.